IL17A and multiple sclerosis: NR4A1 expression in peripheral blood mononuclear cells was low during the preclinical stage of multiple sclerosis, and INF-γ and IL-17 production by proinflammatory Th1/Th17 cells in the central nervous system was decreased after NR4A1 agonist cytosporone B treatment [29].